PAMP
PACB icon

Polar Asset Management Partners’s Pacific Biosciences PACB Stock Holding History

Polar Asset Management Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,800
Closed -$100K – 417
2019
Q1 		$100K Hold
13,800
– – ﹤0.01% 321
2018
Q4 		$102K Buy
+13,800
New +$87.4K ﹤0.01% 320

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Polar Asset Management Partners's PACB Position: Q1 2024 in Review

Polar Asset Management Partners sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 322,800 shares — an estimated $3.17M sold.

Polar Asset Management Partners first reported a position in PACB in Q1 2019 and held it in 7 quarters. The position peaked at $7.66M in Q1 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Polar Asset Management Partners reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 322,800 Pacific Biosciences shares in Q1 2024, an estimated $3.17M.
  • Polar Asset Management Partners first reported a position in Pacific Biosciences in Q1 2019 and held it in 7 quarters.
  • Polar Asset Management Partners's Pacific Biosciences position peaked at $7.66M in Q1 2023.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Polar Asset Management Partners's 13F filing for Q1 2024, filed 15 May 2024.